The failure of many clinical trials suggests inefficacy in the treatment of AD using only one target. This study used multiple targets through a nano-drug protoporphyrin IX (PX) modified oxidized mesoporous carbon (OMCN) nanospheres (PX @ OMCN @ PEG (OP) @RVGs), which appears to be an efficient inhibitor of phosphorylated tau. Also, PX, together with FUS, significantly reduced b-amyloid plaque aggregation. The gene discussed is MAPT; the disease is Alzheimer disease.